<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:hpo ids='HP_0005110'>Atrial fibrillation</z:hpo> (AF) is the most common <z:hpo ids='HP_0011675'>arrhythmia</z:hpo> in athletes </plain></SENT>
<SENT sid="1" pm="."><plain>Evidence supports that it occurs more frequently in endurance athletes than in nonathletes and that it can result in decreased performance or even ineligibility for athletes </plain></SENT>
<SENT sid="2" pm="."><plain>Although there is no clear etiology of why the increase in athletes exists, three supported mechanisms include morphologic adaptation, autonomic alteration, and <z:hpo ids='HP_0011010'>chronic</z:hpo> systemic <z:mp ids='MP_0001845'>inflammation</z:mp> </plain></SENT>
<SENT sid="3" pm="."><plain>Although treatment in athletes can be challenging, type 1C antiarrhythmics are accepted generally as a first-line therapy in addition to risk factor-based anticoagulation </plain></SENT>
<SENT sid="4" pm="."><plain>Radiofrequency catheter ablation also has become a recommended treatment for symptomatic paroxysmal AF that is refractory to at least one class 1 or 3 antiarrhythmic medication and a reasonable treatment in symptomatic paroxysmal AF prior to initiation of antiarrhythmic therapy </plain></SENT>
</text></document>